Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.InterMune grants Danoprevir rights to Roche
With this transaction, InterMune and Roche have terminated the collaboration agreement that the companies had forged in October 2006. InterMune stated that it will make no further investment
With this transaction, InterMune and Roche have terminated the collaboration agreement that the companies had forged in October 2006. InterMune stated that it will make no further investment
Ista Pharma said that the Phase 1/2 study was a double-masked, randomised, placebo-controlled, parallel-group study evaluating the safety and efficacy of three concentrations of Bepotastine besilate, dosed twice
The contract includes an upgrade of all US sales teams to Mobile Intelligence, as well as a suite of implementation and support services. Mobile Intelligence allows for cost-effective
VeriPsych is a molecular diagnostic tool designed to complement the healthcare provider’s clinical impression. VeriPsych, based on the simultaneous measurement of 51 different protein and hormone biomarkers with
MP4 molecule is an investigational biopharmaceutical product designed to enhance the perfusion and oxygenation of oxygen-deprived tissues and provide targeted oxygen delivery to the capillaries in severely injured
Nu Skin claimed that the ageLOC Vitality is formulated to improve three dimensions of vitality, including physical vigor, mental acuity and sexual health, by promoting healthy gene activity
SVGI is a new company formed by Synthetic Genomics and the not-for-profit research institute, the J Craig Venter Institute (JCVI). As per the pact, Novartis and SGVI will
BXL1H5 is a novel monoclonal antibody that binds to TrkA receptors or targets used in developing treatments to tackle pain. The license for the process involving TrkA receptors
To support the marketing application, the company has also provided the positive results of a Phase 3 efficacy trial which met primary endpoint and showed safety profile consistent
Instem claimed that Provantis is a preclinical research technology solution that is easy to use and will offer dual language operation and protocol-driven automation that will produce quality